HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compliance For ‘Gluten Free’ Claims For Fermented, Hydrolyzed Supplements Relies On Recordkeeping

Without Reliable Testing, US FDA Will Ask For ‘Information That Provides Adequate Assurance’

Executive Summary

Final rule amends FDA regulation on gluten-free labeling to provide alternative means for the agency to verify compliance. It will determine whether a firm is compliant from records it must maintain, and make available for inspection and copying, of the fermented or hydrolyzed supplements and food products bearing the claim.

You may also be interested in...



'Landmine' Of Consequences In Nutrition, Supplement Facts Label Changes

FDA’s final rule updating Nutrition Facts labels will have a far-reaching impact on products beyond labeling. The requirements also will change nutrient daily values, potentially affecting product claims and the way in which consumers perceive products, say food consultants during an FDLI webinar.

US-Canada Pilot Could Help FDA's OTC Monograph Update Fly

HHS' latest semi-annual regulatory agenda lists a US-Canada Regulatory Cooperation Council pilot program as the source of a proposed rule to add the common cold indication for monograph OTC antihistamine ingredients that FDA plans to introduce in March 2016.

FDA Proposes Rule On Gluten-Free Labeling

Food products with "gluten-free" claims will be misbranded if they do not meet the conditions of a proposed rule FDA published in the Jan. 23 Federal Register

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel